Therapeutic advances in leiomyosarcoma.
Therapeutic advances in leiomyosarcoma.
复制标题
DOI：
10.3389/fonc.2023.1149106
复制
发表时间：
2023
影响因子：
4.7
通讯作者：
中科院分区：
文献类型：
--
作者：
平滑肌肉瘤是一种侵袭性的间叶性恶性肿瘤，是软组织肉瘤中最常见的亚型之一。其特征在于具有显著的疾病异质性，具有可变的起源位点和多样的基因组谱。因此，晚期平滑肌肉瘤的治疗具有挑战性。转移性和/或不可切除的平滑肌肉瘤的一线治疗包括基于蒽环类或吉西他滨的方案，其提供约5个月的中位无进展生存时间和14-16个月的总生存时间。有效的后线治疗是有限的。分子分析增强了我们对平滑肌肉瘤病理生理学的认识，为治疗提供了潜在的靶点。在这篇综述中，我们探讨了平滑肌肉瘤肿瘤生物学的最新进展和新的治疗方法的影响。我们描述了基于这些发现的临床试验的发展，并讨论了现有的已发表的结果。迄今为止，晚期平滑肌肉瘤最有希望的方法包括靶向DNA损伤修复途径和与肿瘤发生相关的异常代谢，以及新的化疗组合。本文就晚期平滑肌肉瘤的治疗进展作一综述。持续的进展取决于基于分子发现的临床试验的进一步发展，仔细考虑临床试验设计，强有力的学术合作和前瞻性相关分析。
Leiomyosarcoma is an aggressive mesenchymal malignancy and represents one of the most common subtypes of soft tissue sarcomas. It is characterized by significant disease heterogeneity with variable sites of origin and diverse genomic profiles. As a result, the treatment of advanced leiomyosarcoma is challenging. First-line therapy for metastatic and/or unresectable leiomyosarcoma includes anthracycline or gemcitabine based regimens, which provide a median progression-free survival time of about 5 months and overall survival time between 14-16 months. Effective later-line therapies are limited. Molecular profiling has enhanced our knowledge of the pathophysiology driving leiomyosarcoma, providing potential targets for treatment. In this review, we explore recent advances in our understanding of leiomyosarcoma tumor biology and implications for novel therapeutics. We describe the development of clinical trials based on such findings and discuss available published results. To date, the most promising approaches for advanced leiomyosarcoma include targeting DNA damage repair pathways and aberrant metabolism associated with oncogenesis, as well as novel chemotherapy combinations. This review highlights the recent progress made in the treatment of advanced leiomyosarcoma. Ongoing progress is contingent upon further development of clinical trials based on molecular findings, with careful consideration for clinical trial design, strong academic collaborations, and prospective correlative analyses.
登录
查看更多内容
影响因子：
8
作者：
Beck, A. H.;Lee, C-H;Witten, D. M.;Gleason, B. C.;Edris, B.;Espinosa, I.;Zhu, S.;Li, R.;Montgomery, K. D.;Marinelli, R. J.;Tibshirani, R.;Hastie, T.;Jablons, D. M.;Rubin, B. P.;Fletcher, C. D.;West, R. B.;van de Rijn, M.
通讯作者：
van de Rijn, M.
影响因子：
16
作者：
Choe KN;Moldovan GL
通讯作者：
Moldovan GL
影响因子：
16.6
作者：
Anderson ND;Babichev Y;Fuligni F;Comitani F;Layeghifard M;Venier RE;Dentro SC;Maheshwari A;Guram S;Wunker C;Thompson JD;Yuki KE;Hou H;Zatzman M;Light N;Bernardini MQ;Wunder JS;Andrulis IL;Ferguson P;Razak ARA;Swallow CJ;Dowling JJ;Al-Awar RS;Marcellus R;Rouzbahman M;Gerstung M;Durocher D;Alexandrov LB;Dickson BC;Gladdy RA;Shlien A
通讯作者：
Shlien A
DOI：
10.1097/coc.0b013e3181d26d5e
发表时间：
2011-02
期刊：
American journal of clinical oncology
影响因子：
--
作者：
Ganjoo KN;Witten D;Patel M;Espinosa I;La T;Tibshirani R;van de Rijn M;Jacobs C;West RB
通讯作者：
West RB
影响因子：
7.3
作者：
Gibault, Laure;Perot, Gaelle;Aurias, Alain
通讯作者：
Aurias, Alain